Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Jul 7;128(1):13-5.
doi: 10.1182/blood-2016-05-711796.

IL-2, the next best thing in chronic GVHD therapy?

Lauren M Curtis  1 , Steven Z Pavletic  1
Affiliations
Comment

IL-2, the next best thing in chronic GVHD therapy?

Lauren M Curtis et al. Blood. .

Abstract

In this issue of Blood, Koreth et al have reported that interleukin-2 (IL-2) is effective in chronic graft-versus-host disease (cGVHD) patients who had failed up to two prior lines of therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
IL-2 induces both Treg expansion and an increase in the median Treg:Tcon ratio, which subsequently decreases when IL-2 therapy is withdrawn. NR, nonresponder; R, responder. See Figure 2A-B in the article by Koreth et al that begins on page 130.
See this image and copyright information in PMC

Comment on

References

    1. Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016;128(1):130–137. - PMC - PubMed
    1. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055–2066. - PMC - PubMed
    1. Arai S, Arora M, Wang T, et al. Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266–274. - PMC - PubMed
    1. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17. - PubMed
    1. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124(3):374–384. - PMC - PubMed